Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. The program, conducted in collaboration with Dalton Pharma Services, established a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
The milestone strengthens the company’s chemistry, manufacturing, and controls (CMC) framework, following recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. Onco-Innovations stated that the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
This development is significant as it provides a foundation for reproducible and reliable manufacturing of ONC010, which is essential for regulatory submissions and eventual clinical trials. The company's progress in CMC activities indicates a move toward commercialization of its oncology pipeline. For more details, the full press release is available at https://ibn.fm/EefIN.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company aims to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumors. The latest news and updates regarding ONNVF can be found in the company’s newsroom at https://ibn.fm/ONNVF.
BioMedWire (BMW) is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and corporate communications solutions. For more information, visit https://www.BioMedWire.com. This article includes paid advertising and was disseminated on behalf of Onco-Innovations Limited.
